Category: 37480-41-4

On June 30, 2016, Ioannidis, Stephanos; Talbot, Adam Charles; Follows, Bruce; Buckmelter, Alexandre Joseph; Wang, Minghua; Campbell, Ann-Marie; Schmidt, Darby Rye; Guerin, David Joseph; Caravella, Justin A.; Diebold, R. Bruce; Ericsson, Anna; Lancia, David, Jr. published a patent.Category: esters-buliding-blocks The title of the patent was Preparation of pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors. And the patent contained the following:

The invention relates to inhibitors of ubiquitin-specific protease 7 (USP7) of formula I useful in the treatment of cancers, neurodegenerative diseases, immunol. disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases. I [wherein X1 = C, S, or S(O); X2 = CH, CD, C-halo, etc.; R1 = H, D, -OH, etc.; R2 = (C1-C8) alkyl, aryl, heteroaryl, etc.; each R3 independently = D, aryl, heteroaryl, etc.; R4 = (C1-C6) alkyl, CD3, heteroaryl etc.; R5 and R5′ independently = H, D, (C1-C6) alkyl, (C2-C6) alkenyl, etc.; R6 = H, D, (C1-C6) alkyl, etc.; m = 0, 1, or 2; n = 0, 1, 2, or 3] or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer, thereof, are claimed and exemplified. II was prepared via a multistep process (preparation given). I were evaluated for USP7 inhibitor activity using a Ubitquin-Rhodamine 110 assay (data provided). The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).Category: esters-buliding-blocks

The Article related to pyrrolopyrimidine pyrazolopyrimidine preparation ubiquitin specific protease inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrimidines and Quinazolines and other aspects.Category: esters-buliding-blocks

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On April 8, 2021, Wu, Lingyun; Wang, Cailin; Xu, Xiongbin; Tong, Haijun; Chen, Shuhui published a patent.HPLC of Formula: 37480-41-4 The title of the patent was Preparation of heteroaryl compounds as PD-1/PD-L1 inhibitors for treatment of cancer. And the patent contained the following:

The title compounds represented by general formula I [wherein ring A is selected from Ph, 5-10 membered heteroaryl or 5-10 membered heterocycloalkenyl; L is selected from a single bond, -C(=O)NH-, -CH=CH-, -O-CH2- or -NH-; X is selected from -CH- or N; when Y is selected from a single bond, -CH2- or -CH(CH3)-, Z is selected from NR4, or when Y is selected from NR5, Z is selected from -CH2-, where R4 and R5 are each independently selected from H, C1-6 alkyl, C1-6 alkyl-NH-, C3-8 cycloalkyl, etc.; R1 is selected from H, C1-3 alkyl, C1-3 alkoxy, pyridyl-C1-3 alkane-O- or C1-3 alkyl-NH-; R2 and R3 are each independently selected from H, F, Cl, Br, I, CN, etc.; R6 is selected from H, C1-6 alkyl, C0-6 alkyl-C3-6 cycloalkyl, C0-6 alkyl-3-10 membered heterocycloalkyl, C0-6 alkyl-NH-C1-6 alkyl, etc.] or pharmaceutically acceptable salts or isomers thereof were prepared as PD-1/PD-L1 inhibitors. For example, compound II was prepared in a multi-step synthesis. The title compounds can be used for the treatment of cancers. The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).HPLC of Formula: 37480-41-4

The Article related to preparation heteroaryl compound pd1 pdl1 inhibitor treatment human cancer, benzoxazole pyridine naphthalene thiazole pyrazine pyrazole pyrimidine, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.HPLC of Formula: 37480-41-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 9, 2016, Chen, Austin; Bravo, Yalda; Stock, Nicholas; Pedram, Bijan; Jacintho, Jason; Clark, Ryan C.; Truong, Yen published a patent.Application of 37480-41-4 The title of the patent was Thio-substituted benzamides as antiviral agents for the treatment of treatment HBV infection and their preparation. And the patent contained the following:

The invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of formula I. Compounds of formula I wherein each R1, R2, and R3 are halo; R4 is (un)substituted C3-7 cycloalkyl (un)substituted C1-6 alkyl-C3-7 cycloalkyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by thioetherification of N-(3,4,5-trifluoromethylphenyl)-4-fluoro-3-iodobenzamide with 1-(mercaptomethyl)cyclopropylacetic acid. The invention compounds were evaluated for their antiviral activity (some data given). The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).Application of 37480-41-4

The Article related to thiobenzamide preparation antiviral treatment hbv infection, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Application of 37480-41-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On June 2, 2016, Chen, Austin; Bravo, Yalda; Stock, Nicholas; Pedram, Bijan; Jacintho, Jason; Clark, Ryan C. published a patent.Application of 37480-41-4 The title of the patent was Preparation of alkylthio arylamides for HBV treatment. And the patent contained the following:

The invention relates to preparation of alkylthio arylamides of formula I wherein R1-R4 are as defined in the disclosure, a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention. The example compound II was prepared according the disclosed procedure and was tested for HBV inhibiting activity (data shown). Compounds I can be used in treatment and prevention of hepatitis B alone or in combination with other drugs. The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).Application of 37480-41-4

The Article related to alkylthio arylamide preparation antiviral hepatitis b therapy, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Application of 37480-41-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On October 29, 1992, Koda, Akihide; Waragai, Koji; Ono, Yutaka; Ozawa, Hideyuki; Kawamura, Hideki; Maruno, Masao published a patent.Safety of Methyl 1-methyl-4-oxocyclohexanecarboxylate The title of the patent was Preparation of cinnamic acid derivatives as allergy type IV reaction inhibitors. And the patent contained the following:

The title compounds, e.g., cinnamamide derivatives [I; L = (CH:CH)k, (CH2)k; j = 1-6; k = 0-5; R1-R4 = H, NH2, acylamino, di(C1-5 alkyl)amino, halo, HO, AcO, C1-3 alkoxy, CF3, NO2, tetrahydropyranyloxy, PhCH2O; R1R2 = OCH2O) and cinnamic acid esters [II; X3 = CH, COH; R18 = H, C1-6 alkyl; R19 = H, C1-6 alkyl, aryl; R20, R21 = H, C1-6 alkyl, CO2H, its C1-6 alkyl or aryl ester], acting against the effector phase of type IV allergy reactions, are prepared Thus, amidation of 4-(dimethylamino)cinnamic acid with N-[2-(dimethylamino)ethyl]-trans-4-methylcyclohexylamine in CH2Cl2 containing (EtO)2POCl, Et3N, and 4-(dimethylamino)pyridine gave N-[2-(dimethylamino)ethyl]-N-trans-4-methylcyclohexyl)-4-(dimethylamino)cinnamamide (III) which at 3.46 × 10-4 mol/kg p.o. inhibited 100% sheep red blood cell (SRBC)-induced allergy type IV reaction in legs of SRBC-sensitized mice. A tablet formulation containing III was described. A total of 251 cinnamic acid derivatives were prepared The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).Safety of Methyl 1-methyl-4-oxocyclohexanecarboxylate

The Article related to cinnamic acid preparation allergy inhibitor, cinnamamide preparation allergy inhibitor, type iv allergy reaction inhibitor, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Amides, Amidines, Imidic Esters, Hydrazides, and Hydrazonic Esters and other aspects.Safety of Methyl 1-methyl-4-oxocyclohexanecarboxylate

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On August 3, 1983, Kawamatsu, Yutaka; Fujita, Takeshi published a patent.Recommanded Product: 37480-41-4 The title of the patent was Thiazolidine derivatives. And the patent contained the following:

Thiazolidinediones I (R = oxocyclohexyl, hydroxycyclohexyl, methyloxocyclohexyl, methylhydroxycyclohexyl) were prepared, and they exhibited antidiabetic activity. 4-(3-Hydroxy-1-methyl-1-cyclohexylmethoxy)-1-nitrobenzene was treated with H over Pd/C, the aniline analog obtained was diazotized and treated with CH2:CHCO2Me to yield a Me 3-phenylpropionate derivative, and the latter was heated with thiourea and NaOAc to give I (R = 3-hydroxy-1-methylcyclohexyl). The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).Recommanded Product: 37480-41-4

The Article related to thiazolidinedione cyclohexylmethoxybenzyl preparation hypoglycemic, cyclohexylmethoxybenzylthiazolidinedione preparation hypoglycemic, antidiabetic cyclohexylmethoxybenzylthiazolidinedione preparation and other aspects.Recommanded Product: 37480-41-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

On March 20, 2003, Shimano, Masanao; Kamei, Noriyuki; Tanaka, Tomohiro; Harada, Tatsuhiro; Haino, Makoto; Okuyama, Akihiko; Arakawa, Yoshio; Murakami, Yoshiko published a patent.Computed Properties of 37480-41-4 The title of the patent was Preparation of reverse hydroxamic acid derivatives as selective inhibitors of TNF-α converting enzyme (TACE). And the patent contained the following:

Reverse hydroxamic acid derivatives, i.e. N-[2-[[(hetero)arylalkoxy](hetero)arylsulfonyl]ethyl] hydroxamic acid derivatives having specific structures represented by the general formula A-CON(OH)C(R1)(R2a)CH2SO2-Ar1-OCH2Ar2 [A = H, lower alkyl, cycloalkyl, (un)substituted NH2; Ar1 = arylene or heteroarylene; Ar2 = (un)substituted aryl, aralkyl, heteroaryl, or heteroarylalkyl; R1 = H, (un)substituted lower alkyl, lower alkenyl, or cycloalkyl; R2a = Q, Q1; wherein R5, R6, R16 = H, halo, OH, cyano, CF3, (un)substituted lower alkyl or alkoxy; R17 = H, halo, (un)substituted lower alkyl; R68, R69, R70, R71 = H, (un)substituted lower alkyl; X1, X2, Y1, Y2 = a single bond, O, S, (un)substituted CH2 or NH; Z1, Z2 = O, S, (un)substituted :CH or :NH, O(CH2)rO, S(CH2)r1S, O(CH2)t1S; wherein r, r1, t1 = an integer of 2-4; m1, m2 = an integer of 0-6; n1, n2, q1, q2 = an integer of 0-3; p1, p2 = 0, 1] are prepared These compounds are useful for the treatment of diseases caused by TNF-α. Thus, 4-(4-methanesulfonylphenoxymethyl)-2-methylquinoline was treated with lithium diisopropylamide/hexane-heptane-ethylbenzene in THF at -78° for 30 min, treated dropwise with a solution of (tetrahydro-4-ylidene)acetaldehyde in THF, and stirred for 30 min to give 77% 1-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl]-3-(tetrahydropyran-4-ylidene)propan-2-ol (I). To a solution of I and Et3N in CH2Cl2 was added methanesulfonyl chloride at -10° and stirred at room temperature for 12 h to give 100% 2-methyl-4-[4-[3-(tetrahydropyran-4-ylidene)prop-1-en-1-ylsulfonyl]phenoxymethyl]quinoline which was stirred with hydroxylamine in aqueous THF at room temperature for 64 h and then formylated by a mixture of formic acid and acetic anhydride at room temperature for 1 h to give 27.0% N-hydroxy-N-[2-[4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl]-1-(tetrahydropyran-4-ylidene)ethyl]formamide (II). II and optically active II showed IC50 of 3.5 and 2.2 μM, resp., against TACE and were inactive against MMP1, 2, 3, 8, 9, 13, 14, and 17. II at 3 mg/kg (s.c. injection) in vivo inhibited the Escherichia coli-derived lipopolysaccharide (LPS)-induced production of TNF-α by 74.8% in male Lewis rats. The experimental process involved the reaction of Methyl 1-methyl-4-oxocyclohexanecarboxylate(cas: 37480-41-4).Computed Properties of 37480-41-4

The Article related to reverse hydroxamic acid preparation selective tnf converting enzyme inhibitor, tace selective inhibitor reverse hydroxamic acid preparation, tnf production inhibitor hydroxyquinolinylmethoxybenzenesulfonylethylformamide preparation, hydroxyformamide reverse hydroxamic acid preparation tace inhibitor and other aspects.Computed Properties of 37480-41-4

Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics